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Abstract
Introduction Healthcare professionals tend to consider
common non-alarming drug-related symptoms to be of
little clinical relevance. However, such symptoms can have
a substantial impact on the individual patient. Insight into
patient-reported symptoms could aid pharmacists to iden-
tify improvements in medication treatment, for instance in
the patient interview at the start of a clinical medication
review (CMR).
Objective The objectives of this study were to describe the
numbers and types of patient-reported symptoms assessed
during a CMR and to elucidate their potential association
with the drugs in use.
Methods This observational study was performed using
data from a clinical trial on patient-reported outcomes of
CMRs. Patients taking at least five drugs and who were
eligible for a CMR were selected by 15 community phar-
macies. Patients were asked to fill in a structured instru-
ment, the Patient Reported Outcome Measure, Inquiry into
Side Effects (PROMISE). Among other domains, this
instrument offers a list of 22 symptom categories to report
symptoms and their relationship with the drugs in use. The
results of the PROMISE instrument together with infor-
mation on patients’ actual drug use were available for
analysis. Besides descriptive analysis, associations with
side effects as listed in the summary of product charac-
teristics (SPC) of the drugs in use were assessed with
logistic regression analysis.
Results Of the 180 patients included, 168 patients
(93.3%) reported at least one symptom via the PRO-
MISE instrument, which could be discussed with the
pharmacist during the patient interview. In total, the
patients reported 1102 symptoms in 22 symptom cate-
gories. Of these patients, 101 (56.1%) assumed that at
one or more of the symptoms experienced were related
to the drugs in use and 107 (59.4%) reported at least one
symptom that corresponded to a ‘very common’ side
effect listed in the SPC of a drug in use. Each additional
drug in use with a specific symptom listed as a ‘very
common’ side effect in its SPC statistically significantly
increased the probability of a patient reporting the
symptoms of ‘dry mouth/thirst, mouth complaints’,
‘constipation’, ‘diarrhoea’ and ‘sweating’.
Conclusion Many patient-reported symptoms and
symptoms potentially related to drugs in use were
identified by administering the PROMISE instrument to
users of at least five drugs being taking long-term. This
information can be used in CMRs to improve patients’
drug therapy.
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Key Points
Nearly all users with at least five drugs in long-term
use reported at least one common symptom at the
start of a clinical medication review.
More than half of the patients considered at least one
drug in use to be responsible for a symptom
experienced.
Concomitant use of drugs with the same side effect
as listed in their summary of product characteristics
increased the risk to patients reporting the
corresponding symptoms of ‘constipation’,
‘diarrhoea’, ‘dry mouth/thirst, mouth complaints’
and ‘sweating’.
1 Introduction
Symptoms are subjective signs of a disease or of a patient’s
condition [1] and may be caused by drugs being taken by a
patient. Studies have shown that healthcare professionals
tend to ignore non-alarming drug-related symptoms [2–4].
Instead, they mainly focus on (potentially) serious drug-
related symptoms to prevent major harm to their patients
[5–8]. In order to prevent these major harms, recommen-
dations have been developed [9] and pharmacist-initiated
interventions to avoid potentially preventable hospital
admissions have been proposed [10]. As a consequence,
less attention is paid to the reduction of common non-
alarming symptoms in medication users.
Even when drug-related symptoms are non-alarming, they
can still have a substantial impact on a subject’s daily life. For
instance, dizziness may increase the fear and risk of falling,
muscle pain may reduce physical activity, and diarrhoea may
induce or worsen social isolation. This may also lead to poor
adherence or discontinuation of the drugs in use. Common
non-alarming drug-related symptoms are less likely to be
considered preventable than serious drug-related symptoms
[11, 12]. Therefore, effective intervention strategies for the
detection and amelioration of common drug-related symp-
toms are important to increase quality of life.
Patients taking multiple drugs in long-term use are more
susceptible to adverse effects of drugs [13]. Consequently,
amelioration of patient-experienced adverse effects should
be a prominent part of a clinical medication review (CMR),
aimed at optimising drug effectiveness and safety in patients
with at least five drugs in long-term use. In The Netherlands,
CMRs are performed by pharmacists in cooperation with
general practitioners (GPs) according to the Dutch guideli-
nes for CMRs [14, 15]. These guidelines distinguish six
steps: patient selection, a patient interview, a medication
analysis, a pharmaceutical care plan, implementation of
recommendations, and a follow-up evaluation 3 months
later. During the patient interview at the start of the CMR,
patient-reported symptoms should be taken into account to
prioritise further adjustment of the drug regimen [16–18]. As
patients may fail to spontaneously report common drug-re-
lated symptoms, a self-report instrument may be helpful to
detect potential drug-related symptoms [19].
While patients may not recognise all drug-related
symptoms as such, awareness may be increased by asking
about any experienced symptoms. In a cross-sectional
study in the general Norwegian population (between 15
and 84 years), 96% of subjects reported subjective health
complaints [20]. Hence, it may be expected that nearly all
patients qualifying for a CMR will report one or more
symptoms that may or may not be related to their drugs in
use. By using an instrument to identify symptoms in
advance, during the patient interview at the start of a CMR
the pharmacist can focus on the evaluation and possible
amelioration of these symptoms, especially when they
appear to be drug related. The side effects of a drug are
listed in its summary of product characteristics (SPC) by
frequency of occurrence. Hence, SPCs are regularly con-
sulted to assess whether symptoms are potentially drug
related [14, 21]. The aims of the present study were to
describe the numbers and types of patient-reported symp-
toms assessed during a CMR and to elucidate an associa-
tion between these symptoms and a patient’s drugs in use
as indicated by the patient or when compared with the side
effects listed in the SPCs of these drugs.
2 Methods
2.1 Study Design
The data for this cross-sectional observational study were
collected within the context of a randomised clinical trial
on the effect of pharmacists’ interventions to reduce
patient-reported drug-related symptoms in CMRs. In this
trial (registered as number 4895 in the Netherlands Trial
Register; http://www.trialregister.nl), after providing
informed consent patients were randomised into an inter-
vention group and a control group (unpublished data). All
patients were invited to fill in a paper instrument, the
Patient Reported Outcome Measure, Inquiry into Side
Effects (PROMISE) twice: first, at the beginning of the
study about 2 weeks before the patient interviews in the
intervention group and, second, before the evaluation of
treatment changes 3 months later. For this study, only the
PROMISE data from the first measurement were used. The
Arnhem-Nijmegen ethical committee determined that
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ethical approval for the trial was not mandatory (registra-
tion number 2014/320).
2.2 Setting and Participants
2.2.1 Clinical Medication Review
In a CMR, drug therapy-related problems (DTPs) can be
identified by judging the appropriateness of the drugs in
use in combination with patient characteristics and labo-
ratory values, as well as by interviewing patients in relation
to problems regarding their drug use. The patient interview
at the start of a CMR enables the pharmacist to focus on
DTPs relevant from a patient perspective, such as drug-
related symptoms [16–18]. In the trial mentioned in Sect.
2.1, input for these DTPs was provided by administering
the PROMISE instrument.
2.2.2 Patient Reported Outcome Measure, Inquiry
into Side Effects (PROMISE)
PROMISE is a concise instrument used to collect informa-
tion on proper medication use that was developed to be used
in the trial outlined in Sect. 2.1. It comprises five predefined
domains: health status, beliefs and concerns about medici-
nes, self-efficacy in understanding and using medicines,
medication adherence, and potentially drug-related symp-
toms. Additionally, an open-ended question enables the
patient to propose any issues to be discussed during the
interview with the pharmacist. The first four domains were
derived from existing instruments [22–25]. For the fifth
domain, an item list of common symptoms was chosen to be
used as such a list has been proven to be more sensitive to
complete reporting than open-ended questions [26]. The
item list should fit in the concise design of the PROMISE
instrument and contain symptoms relevant for use in a
CMR. For this reason a standardised list of specific symp-
toms was developed based on the most common side effects
of drugs most frequently used in The Netherlands. To this
end, information on volumes of drug use in The Netherlands
was retrieved from the health insurance database (GIP
[Genees-en hulpmiddelen Informatie Project] database) and
the Dutch Foundation for Pharmaceutical Statistics
(Stichting Farmaceutische Kengetallen [SFK]) [27, 28]. The
top 100 drugs were chosen from the GIP database as those
with the most defined daily doses and were complemented
with two drugs (amoxicillin, doxycycline) from the top 100
users [27]. As the GIP database only included reimbursed
drugs, the list was complemented with two drugs (ox-
azepam, sildefanil) from the top five non-reimbursed drugs
as published by the SFK [28]. All drugs were classified by
the anatomic therapeutic chemical (ATC) classification
[29]. For each drug class, the most frequently used
representative was selected (e.g. simvastatin within statins
[HMG-CoA reductase inhibitors] and omeprazole within
proton pump inhibitors)—48 drugs in total (see Electronic
Supplementary Material 1). The side effects of these 48
drugs, as listed in their SPCs at a frequency of at least 1%,
from here on addressed as side effects, were collected from
Apotheek.nl, a website with online drug information in lay
language that can be understood by patients [30]. Thus, the
side effects obtained were scored based on the number of
drugs multiplied by a weight factor for the frequency as
listed in Apotheek.nl (1 for 1–10%, 2 for 10–30%, 3 for
C30%). Subsequently, the side effects were translated into a
total of 165 related symptoms. These symptoms (e.g. nau-
sea, vomiting) were grouped according to International
Classification of Primary Care-Second Edition (ICPC-2)
classification codes by one of the researchers (TS), resulting
in 65 symptom categories [31]. Subsequently, the same
researcher (TS) ranked the symptom categories in
descending order on the scores allocated, and set up a
pragmatic cut-off point within the list to comprise the most
common symptoms without overloading the patient. Both
the symptom categories and cut-off point were indepen-
dently reviewed by the other researchers (MT, MW, PdS).
The symptoms were compared with symptoms listed in the
literature, and no further omissions were found. The final set
of the 22 most frequently occurring symptom categories was
agreed in a consensus meeting of all researchers. Patients
could also report additional symptoms if needed.
Finally, all domains were combined into one instrument
that was sent to two groups of ten community pharmacists
each to check for usability in common practice. This did
not result in any changes in the instrument, but yielded
meaningful information for its implementation as part of
CMRs such as written instructions on how to use patient
responses in clinical practice. Additionally, the instrument
was pretested in patients eligible for a CMR to assess
whether the items were well-understood. Using cognitive
interviewing, patients were asked to fill in the form by
thinking out loud and supplementary questions to sub-
stantiate their answers were asked when needed. In total,
six individual interviews were held, with an evaluation
after three interviews resulting in slight changes in the
instrument. After six interviews no new insights were
gained. The cognitive interviews led to textual and layout
improvements, rearrangement of the symptoms into a
logical order, and simplification of the answer categories in
the symptom domain. In this final version of the PROMISE
instrument, patients were asked to report all symptoms
experienced in the last month (yes, no). They were also
asked to indicate whether they associated these symptoms
with one of their drugs in use (yes, perhaps, no). Symptoms
with the answer ‘yes’ on the second question are from here
on addressed as drug-associated symptoms.
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2.2.3 Pharmacist Selection
Pharmacists from 15 community pharmacies participated in
this study. They were all users of the same online pharma-
ceutical care support system, which includes a tool to sup-
port the implementation of CMRs. The participating
pharmacies were a convenience sample from 11 munici-
palities, urban as well as rural, spread over The Netherlands.
All participating pharmacists were trained and experienced
in performing CMRs according to the Systematic Tool to
Reduce Inappropriate Prescribing (STRIP) [32], as described
in the Dutch guideline for CMRs [14, 15]. Additionally, the
pharmacists received written instructions for the sampling of
patients and for the data collection for this study.
2.2.4 Patient Sample
Patients were considered eligible for participation follow-
ing the guideline-based inclusion criteria for CMRs, except
that cognitive disability was an exclusion criterion due to
the need for a patient to complete the instrument [14, 15].
‘Chronic use of at least five drugs’, the main inclusion
criterion, was determined by means of the online tool.
Subsequently, further sampling was applied by pharmacists
based on additional risk factors such as age over 65 years,
co-morbidities (e.g. renal dysfunction), decreased adher-
ence and use of risk medication without protective co-
medication (e.g. people[70 years using NSAIDs without
adequate gastroprotection). Additionally, practical criteria
were applied, such as good cooperation with the patient’s
GP or reimbursement of a fee for the CMR by the patient’s
health insurance company. A patient’s ability to complete
the instrument and participate in an interview was deter-
mined in cooperation with their GP. The pharmacists
invited all selected patients by telephone or mail for a
CMR and to take part in the study between September 2014
and September 2015.
2.3 Data Collection
2.3.1 Patient-Reported Symptoms and Drugs in Use
Patients completed the PROMISE instrument at home or in
the pharmacy just before the interview. The pharmacists
then passed on the completed PROMISE data and infor-
mation on actual drug use and the patient’s sex and age to
the researcher, all provided using an anonymous patient
code. In The Netherlands, community pharmacists have
access to patients’ actual drug use through their community
pharmacy information system. An actual drug list was
retrieved for each patient, from which the dispensed drugs
covering the month before completing the PROMISE
instrument were considered to be in use.
2.3.2 Side Effects of Drugs in Use
All of the SPC-listed side effects for the drugs in use
and their frequencies were retrieved to enable a com-
parison with the patient-reported symptoms. This was
performed in a likewise procedure as in the develop-
ment of the PROMISE instrument but with some dif-
ferences. For this purpose, the side effects were
primarily retrieved from the Royal Dutch Pharmacists
Association’s online drug database (KNMP Kennisbank)
which contains drug information for pharmacists [33]
that is derived from the SPCs [34]. If the KNMP Ken-
nisbank lacked specific information about the frequency
of side effects listed for a specific drug, additional
information was collected from Apotheek.nl [30]. The
information in Apotheek.nl is derived from the data in
the KNMP Kennisbank and extended using other sour-
ces if necessary to describe patient-oriented information
in lay language and to convert clinical manifestations
into symptoms. The frequency of side effects is listed
by category in the SPCs, e.g. side effects with a fre-
quency of C10% are categorised as ‘very common’,
1–10% as ‘common’, and 0.1–1% as ‘uncommon’ side
effects [34]. In our study, we only collected information
on ‘very common’ and ‘common’ listed side effects of
all drugs being taken by patients who reported at least
one symptom. All side effects, including clinical man-
ifestations, were listed and converted into the corre-
sponding symptom category of the PROMISE
instrument independently by two researchers (TS, PdS).
Clinical manifestations were translated into one or more
of the predominant symptoms in the PROMISE instru-
ment (e.g. hypoglycaemia was converted to change of
appetite, trembling, headache, dizziness, tiredness, and
sweating). Disagreements between the two researchers
were discussed until consensus was reached. If different
frequencies were listed for the corresponding side
effects in composite symptoms (e.g., ‘nausea, vomit-
ing’), the highest frequency was assigned. Thus,
obtained ‘very common’ side effects were compared
with the patient-reported symptoms. Patient-reported
symptoms that aligned with a side effect of one or more
drugs in use are from here on addressed as SPC-
associated symptoms.
2.4 Outcome Measures
The following outcomes were measured in this study: the
number of patients reporting a predefined symptom, the
number of patients reporting this as a drug-associated
symptom, and the number of patients reporting a symptom
that was a ‘very common’ side effect in at least one of their
drugs in use (‘SPC-associated symptom’).
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2.5 Analysis
All data were registered in an Access 2007 database
(Microsoft Corp., Redmond, WA, USA). Drugs were reg-
istered using the 2013 version of the ATC classification
system of the World Health Organization [29]. Drugs were
mainly registered at the ATC-5 level (of drug substance),
except for some drugs such as insulin (A10A) or calcium in
combination with colecalciferol (A12AX) that were regis-
tered at a higher ATC level. All other composite prepara-
tions were registered separately for each of the constituents
(e.g. salmeterol and fluticasone).
Numbers of patients reporting a symptom, a drug-as-
sociated symptom and an SPC-associated symptom were
counted using descriptive statistics. Logistic regression was
used to assess the contribution of each additional drug in
use that had the symptom listed as a ‘very common’ side
effect (predictor) to the probability of a patient reporting a
symptom (outcome), adjusted for sex and age. A p value of
B0.05 was considered statistically significant. Subse-
quently, a Bonferroni correction for multiple testing was
applied with a p value of B0.0023.
For all SPC-associated symptoms, we counted the
numbers of patients using drug classes with these symp-
toms listed as a side effect and the number of users
reporting these symptoms. The outcomes were aggregated
at the ATC-4 level, except for drug classes composed of
drugs with a different pharmacological profile (e.g. other
antidepressants [N06AX]), which were not aggregated but
analysed at the ATC-5 level. Drug classes with five or
more patients reporting an SPC-associated symptom were
considered to be relevant for reporting. In a sensitivity
analysis, in addition to ‘very common’ side effects,
‘common’ side effects were also included. Percentages of
drug users reporting a corresponding SPC-associated
symptom were only compared for drug classes with ten or
more users with the aim of achieving a meaningful
comparison.
Symptoms were counted by means of queries in an
Access 2007 database. Data were exported to SPSS
version 22 (IBM Corp., Armonk, NY, USA) for logistic
regression analysis. The data from both queries and sta-
tistical analysis were aggregated in tables using Microsoft
Excel, 2007 version (Microsoft Corp.).
3 Results
Of the 228 patients with initial informed consent, 180
(78.9%) provided data to this study. The other 48 subjects
either did not answer the PROMISE instrument (32
patients) or withdrew from the study (16 patients). The
mean age of these non-responders was 73 years and
52.1% were female. In comparison, the mean age of the
180 included subjects was 73 years (range 43–89 years)
and 93 (51.7%) were female. The included subjects used a
total of 258 different drugs with a mean of nine per
person (range 5–22). The most prevalent drug classes in
use were proton pump inhibitors (122 patients), statins
(115 patients) and selective b-blocking agents (96
patients) (Table 1).
3.1 Symptoms
Of the 180 included subjects, 168 (93.3%) reported a total
of 1102 predefined symptoms in the PROMISE instrument.
Sixteen patients (8.8%) reported an additional symptom,
e.g. sleeplessness and restless legs. The mean number of
predefined patient-reported symptoms was 6.12 with a
range from 0 to 19 (Table 2). Patients most frequently
reported the following symptoms: ‘muscle pain, joint pain’
(105 patients), ‘weakness, tiredness’ (95 patients) and ‘dry
mouth/thirst, mouth complaints’ (79 patients). Patients
least frequently reported the following symptoms: ‘nausea,
vomiting’ (17 patients), ‘sexual complaints’ (21 patients)
and ‘change of appetite’ (23 patients) (Table 3).
3.2 Drug-Associated Symptoms
In total, 304 drug-associated symptoms, with a mean
number of 1.69 per patient (range 0–13), were reported by
101 (56.1%) of the 180 patients (Table 2). Patients indi-
cated 27.6% of the 1102 reported symptoms to be drug
associated (‘yes’) and 44.3% to be ‘perhaps drug-associ-
ated’ (71.9% together). The percentage of ‘perhaps drug-
associated’ varied between 33 and 54% for nearly all
symptoms, apart from ‘bruises, bleedings’ for which only
17% of the patients were not sure about a drug association.
The following drug-associated symptoms were reported
most frequently: ‘bruises, bleedings’ (46 patients, 65% of
71 patients reporting this symptom), ‘dry mouth/thirst,
mouth complaints’ (34 of 79 patients, 43%) and ‘skin
complaints, itching’ (25 of 68 patients, 37%). The fol-
lowing drug-associated symptoms were reported least fre-
quently: ‘muscular weakness’ (4 of 40 patients, 10%),
‘palpitations’ (4 of 36 patients, 11%) and ‘change of
appetite’ (5 of 23 patients, 22%) (Table 3).
3.3 SPC-Associated Symptoms
Of the 180 patients in total, 107 (59.4%) reported 284
symptoms that were mentioned in the SPCs as being ‘very
common’ side effects of in total 65 drugs in use (SPC-
associated symptoms). Most frequently reported were
‘weakness, tiredness’ (57 patients, 58% of the 95 patients
reporting this symptoms), ‘dry mouth/thirst, mouth
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complaints’ (30 of 79 patients, 38%) and ‘eye irritation,
vision problems’ (24 of 69 patients, 35%) (Table 3). For the
drug classes in use by at least ten subjects in the study
population, the following SPC-associated symptoms were
most frequently reported: aldosterone antagonists—‘weak-
ness, tiredness’ (reported by 9 of the 12 users; 75%); non-
selective monoamine reuptake inhibitors (tricyclic antide-
pressants)—‘dry mouth/thirst, mouth complaints’ (reported
by 7 of 10 users; 70%); prostaglandin analogues—‘eye
irritation, vision problems’ (reported by 7 of 12 users;
58%); selective b-blocking agents—‘weakness, tiredness’
(reported by 45 of 78 users; 58%); and high ceiling
diuretics—‘dry mouth/thirst, mouth complaints’ (reported
by 12 of 21 users; 57%). In relation to specific drug classes,
the SPC-associated symptom ‘constipation’ was reported by
six of nine users of natural opioids (67%) and five of ten
users of tricyclic antidepressants (50%) (Table 4).
In the sensitivity analysis for the relation with SPC-
associated symptoms, in addition to the ‘very common’,
‘common’ side effects were also taken into account. This
increased the number of drugs potentially associated with
the patient-reported symptoms from 65 to 173. In this
analysis, the following SPC-associated symptoms were
reported most often for drug classes with at least ten users
Table 1 Patient characteristics Characteristics Patients (n = 180)
Number of females (%) 93 (51.7)
Mean age [years (range)] 73 (43–89)
Mean number of drugs in use (range) 9 (5–22)




Most frequently used drug classes (ATC code) [number of patients (%)]
Proton pump inhibitors (A02BC) 122 (67.8)
HMG-CoA reductase inhibitors (statins) (C10AA) 115 (63.9)
B-Blocking agents, selective (C07AB) 96 (53.3)
Platelet aggregation inhibitors excluding heparin (B01AC) 81 (45.0)
ACE inhibitors, plain (C09AA) 66 (36.7)
Angiotensin II antagonists (C09CA) 60 (33.3)
Thiazides (C03AA) 55 (30.6)
Dihydropyridine derivatives (C08CA) 52 (28.9)
Biguanides (A10BA) 46 (25.6)
Vitamin K antagonists (B01AA) 41 (22.8)
ATC anatomic therapeutic chemical
Table 2 Overview of
symptoms reported per patient
Characteristics Patients (n = 180)
Mean number of symptoms reported (range) 6.12 (0–19)






Mean number of drug-associated symptoms reported (range) 1.69 (0–13)
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Table 3 Patient numbers for reported symptoms, drug-associated symptoms and SPC-associated symptoms




Number of patients reporting drug-
associated symptoms
OR for reporting a symptom per
additional drug in use with the
symptom listed as a side effecta,b
[OR (95% CI)]Yes Perhaps No Missing
Change of
appetite
All responders 23 5 10 6 2 1.92 (0.80–4.59)
Users with SPC-associated
symptom for C1 drug(s)a




All responders 79 34 33 4 8 1.92 (1.10–3.36)c
Users with SPC-associated
symptom for C1 drug(s)
30 15 11 1 3
Nausea,
vomiting
All responders 17 6 6 4 1 1.54 (0.96–2.46)
Users with SPC-associated
symptom for C1 drug(s)
12 4 5 2 1
Stomach pain,
dyspepsia
All responders 31 10 15 4 2 0 (0–0)
Users with SPC-associated
symptom for C1 drug(s)
0 0 0 0 0
Abdominal pain All responders 26 10 10 4 2 0.85 (0.34–2.11)
Users with SPC-associated
symptom for C1 drug(s)
7 3 3 0 1
Diarrhoea All responders 34 9 17 7 1 1.90 (1.14–3.16)c
Users with SPC-associated
symptom for C1 drug(s)
20 5 12 3 0
Constipation All responders 35 14 14 2 5 3.50 (1.67–7.31)c,d
Users with SPC-associated
symptom for C1 drug(s)
12 7 5 0 0
Flatulence All responders 76 18 38 6 14 1.30 (0.18–9.54)
Users with SPC-associated
symptom for C1 drug(s)




All responders 69 14 33 15 7 1.50 (0.90–2.50)
Users with SPC-associated
symptom for C1 drug(s)
24 7 10 6 1
Palpitations All responders 36 4 19 10 3 2.60 (0.78–8.65)
Users with SPC-associated
symptom for C1 drug(s)
5 2 2 0 1
Trembling,
shivering
All responders 37 6 20 5 6 2.74 (0.83–9.09)
Users with SPC-associated
symptom for C1 drug(s)
5 1 2 1 1
Muscle pain,
joint pain
All responders 105 19 41 30 15 0.44 (0.16–1.23)
Users with SPC-associated
symptom for C1 drug(s)
7 0 1 4 2
Muscular
weakness
All responders 40 4 20 11 5 0 (0–0)
Users with SPC-associated
symptom for C1 drug(s)
0 0 0 0 0
Headache All responders 41 5 22 8 6 1.25 (0.88–1.77)
Users with SPC-associated
symptom for C1 drug(s)




All responders 57 11 29 11 6 1.17 (0.76–1.81)
Users with SPC-associated
symptom for C1 drug(s)
23 3 11 4 5
Weakness,
tiredness
All responders 95 18 47 21 9 1.40 (0.90–2.16)
Users with SPC-associated
symptom for C1 drug(s)
57 14 25 12 6
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in the study population: anticholinergic inhalants—‘dry
mouth/thirst, mouth complaints’ (symptom reported by 20
of 24 users; 83%); and glucocorticoid inhalants—‘muscle
pain, joint pain’ (reported by 17 of 22 users; 77%). Only 12
of 40 statin users (30%) reported ‘muscle pain’ as a
‘common’ side effect (see Electronic Supplementary
Material 2).
3.4 Association Between Symptoms and Drugs
in Use
Use of a drug with a specific symptom listed as a ‘very
common’ side effect in its SPC statistically significantly
increased the probability of a patient reporting this symp-
tom with each additional drug: ‘constipation’ by 3.50 (95%
confidence interval [CI] 1.67–7.31); ‘sweating’ by 2.70
(95% CI 1.15–6.33); ‘dry mouth/thirst, mouth complaints’
by 1.92 (95% CI 1.10–3.36); and ‘diarrhoea’ by 1.90 (95%
CI 1.14–3.16). After correction for multiple testing, only
the association for added influence of several drugs on
reporting ‘constipation’ remained statistically significant
(Table 3).
4 Discussion
Of users of at least five drugs used long-term who were
selected for a CMR, 93.3% reported at least one symptom
on the PROMISE instrument, which was in line with earlier
studies [20, 35]. In total, 1102 symptoms spread over 22
predefined symptom categories were reported by 168
patients. Patient numbers per category varied from 21
patients reporting ‘nausea, vomiting’ to 105 reporting
‘muscle pain, joint pain’. At least one symptom was indi-
cated as being drug associated by 56.1% of the patients,
mostly ‘bruises, bleedings’ (46 patients). In 59.4% of the
patients, at least one of their symptoms reported could be
traced to a ‘very common’ side effect of at least one drug in
use according to the SPC information. These ‘SPC-asso-
ciated symptoms’ were mostly ‘weakness, tiredness’ (57
patients), with the majority (45 patients) using metoprolol.
The patient-reported symptom categories ‘dry mouth/thirst,
mouth complaints’, ‘constipation’, ‘diarrhoea’ and
‘sweating’ were associated with an increasing number of
drugs in use that had the symptom listed as a ‘very com-
mon’ side effect in the SPC.
Table 3 continued




Number of patients reporting drug-
associated symptoms
OR for reporting a symptom per
additional drug in use with the
symptom listed as a side effecta,b
[OR (95% CI)]Yes Perhaps No Missing
Drowsiness All responders 59 16 32 7 4 1.30 (0.83–2.04)
Users with SPC-associated
symptom for C1 drug(s)
20 7 9 2 2
Change of mood All responders 35 7 16 7 5 NA
Users with SPC-associated
symptom for C1 drug(s)
1 0 0 1 0
Sexual
complaints
All responders 21 11 7 3 0 1.34 (0.41–4.42)
Users with SPC-associated
symptom for C1 drug(s)
4 2 2 0 0
Bruises,
bleedings
All responders 71 46 12 6 7 0.64 (0.12–3.33)
Users with SPC-associated
symptom for C1 drug(s)
2 0 2 0 0
Skin complaints,
itching
All responders 68 25 29 10 4 1.52 (0.66–3.48)
Users with SPC-associated
symptom for C1 drug(s)
8 3 4 1 0
Sweating All responders 47 12 18 10 7 2.70 (1.15–6.33)c
Users with SPC-associated
symptom for C1 drug(s)
14 7 3 3 1
NA not applicable, OR odds ratio, SPC summary of product characteristics
a Based on possible associations with all listed ‘very common’ side effects of drugs in use in all subjects
b An OR[1 means that the chance for a patient to report the symptom increases with this factor for every additional drug in use with the
symptom listed as a side effect in the SPC
c Statistically significant (p B 0.05)
d Statistically significant (p B 0.0023) after Bonferroni correction for multiple testing
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In this study, we measured all symptoms reported by
users of at least five drugs in long-term use via a CMR
performed by community pharmacists. Other studies of
community pharmacist-initiated CMRs reported only on
drug-associated symptoms. Krska et al. [18] named a mean
number of 1.9 drug-associated symptoms per patients,
which is in line with the mean number of 1.7 per patient
found in our study. The study by Krska et al. [18] was
performed in a comparative setting of subjects with five or
more drugs being used long-term. They identified the
symptoms by screening health records in combination with
patient interviews rather than with an instrument. Two
other studies in the context of a CMR reported consider-
ably lower mean numbers of symptoms of 0.43 and 0.58
per patient [17, 36]. However, they only reported drug-
associated symptoms that were confirmed by a pharmacist,
which explains the difference from the numbers reported
by patients in our study. The lack of overall patient-re-
ported symptoms in these studies hinders reliable
comparison.
Table 4 Examples of specific drugs/drug classes in patient-reported summary of product characteristics-associated symptomsa
Symptom Drug/drug classb ATC Number of patients
reporting the symptom
(% of users of drug from
this drug class)
Number of patients using a
drug from this drug class with
the symptom listed as a side
effecta
Change of appetite Blood glucose-lowering drugs,
biguanides (metformin)
A10BA 8 (18) 45
Dry mouth/thirst, mouth
complaints
High ceiling diuretics (furosemide) C03CA 12 (57) 21
Antidepressants, non-selective
monoamine reuptake inhibitors
N06AA 7 (70) 10
Nausea, vomiting Blood glucose-lowering drugs,
biguanides (metformin)
A10BA 6 (13) 45
Abdominal pain Blood glucose-lowering drugs,
biguanides (metformin)
A10BA 7 (16) 45
Diarrhoea Blood glucose lowering drugs,
biguanides (metformin)
A10BA 14 (31) 45
Constipation Natural opium alkaloids (oxycodone) N02AA 6 (67) 9
Antidepressants, non-selective
monoamine reuptake inhibitors
N06AA 5 (50) 10
Eye irritation, vision
problems
High ceiling diuretics (furosemide) C03CA 11 (52) 21
Antidepressants, non-selective
monoamine reuptake inhibitors
N06AA 5 (50) 10
Ophthalmologics, prostaglandin
analogues
S01EE 7 (58) 12
Muscle pain, joint pain Bisphosphonates (alendronic acid) M05BA 6 (57) 9
Headache Platelet aggregation inhibitors,
(dipyridamole)
B01AC 5 (33) 15
Organic nitrates C01DA 9 (30) 30
Dizziness, vertigo, fainting Platelet aggregation inhibitors,
(dipyridamole)
B01AC 6 (40) 15
Weakness, tiredness Aldosterone antagonist
(spironolactone)
C03DA 9 (75) 12
b-Blocking agents, specific
(metoprolol)
C07AB 45 (58) 78
Drowsiness Benzodiazepine derivatives N05BA 8 (100) 8
Sweating Antidepressants, non-selective
monoamine reuptake inhibitors
N06AA 5 (50) 10
Other antidepressants, venlafaxine N06AX 5 (83) 6
ATC anatomic therapeutic chemical
a Based on all listed ‘very common’ side effects of drugs in use
b All drug classes (drugs) on the ATC-4 level in the ATC classification system with C5 patients reporting a symptom are displayed. The generic
drug name is displayed in parentheses when only one drug was involved. Drug classes composed of drugs with a different pharmacological
profile (e.g. other antidepressants, N06AX) were not aggregated; when a single drug exceeded the cut-off point the drug name is specified
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In evaluating patient-reported symptoms as drug asso-
ciated, the probability of a drug-related symptom occurring
has to be considered [21, 32]. The probability of drug-
related symptoms occurring can be derived from the fre-
quencies for the side effects as given in the SPCs. How-
ever, the information in the SPC is based on clinical trials
in specific patient populations with a short follow-up per-
iod, and thus may differ from frequencies in clinical
practice [37, 38]. These differences may explain why
muscle pain in statin users is more frequently reported in
clinical practice than that in the SPCs. In SPCs of statins,
‘muscle pain’ is listed as a ‘common’ (1–10%) and for
simvastatin even as an ‘uncommon’ (0.1–1%) side effect,
which is in contrast with the 5–20% found in observational
studies [39]. In our study, 12 of the 40 users of statins with
‘muscle pain’ listed as a ‘common’ side effect reported this
symptom. These findings may illustrate the underestima-
tion of side effect frequencies in SPCs. In addition, the time
of onset or symptom duration can be used to estimate the
likeliness of an association with a drug in use. To illustrate,
lower frequencies for diarrhoea were reported with long-
term metformin use than at the start of metformin therapy
[40, 41].
Inquiring about symptoms regardless of their origin may
be advantageous for the pharmacist in effectively improv-
ing bothersome symptoms experienced by patients, as
patients do not always recognise drug-associated symptoms
as such. An earlier study by de Vries et al. [42] noted that
53% of the symptoms reported were associated by patients
with at least one of their drugs in use. This is in line with
the 71.9% of symptoms that were reported as possibly drug
associated (‘yes’ or ‘perhaps’) in our study. In 44.3% of the
reported symptoms, patients were not certain regarding a
drug association. Such uncertainties are more likely when
concomitant drugs and diseases are involved [43]. In the
patient interview for a CMR, a pharmacist can address such
symptoms by assessing drug use, clinical data and co-
morbidities using structured tools [14, 21]. Besides drugs,
alternative causes for patient-reported symptoms also have
to be taken into account, as these symptoms may be due to
a prevalent or new disease or be a ‘normal’ consequence of
aging [44, 45]. Such reported symptoms may also indicate
an untreated disorder in the patient or a subtherapeutic
effect of an existing drug therapy. For instance, although
‘weakness, tiredness’ is known as a ‘very common’ side
effect of metoprolol and spironolactone, this symptom
could also be a sign of worsened heart failure. The likeli-
ness of an alternative cause may differ between symptom
categories, as is illustrated by the comparison between the
numbers of symptoms and drug-associated symptoms
reported in our findings. In our study population, drugs
were less often indicated as the causes in unspecific
symptoms such as ‘weakness, tiredness’ than in more
specific symptoms such as ‘bruises, bleedings’. The latter
symptom may well be recognised by patients as a well-
known side effect of vitamin K antagonists.
Concomitant use of drugs with the same side effect is
believed to contribute to the probability of reporting the
corresponding symptom. We found an association between
the symptoms ‘diarrhoea’, ‘constipation’, ‘sweating’ and
‘dry mouth/thirst, mouth complaints’ and each additional
drug in use with that symptom listed as a ‘very common’
side effect in the SPC. Consequently, to alleviate these
bothersome symptoms, drug interventions have to be taken
into account. Our findings provide insight into the most
likely candidates. Users of metformin frequently reported
‘diarrhoea’, which is a well-known side effect of this drug
[40]. In the literature, constipation was shown as a side
effect of opioids and tricyclic antidepressants, and this is in
agreement with the findings of our study [9, 16, 46]. Tri-
cyclic antidepressants were also found to be a potential
cause of ‘sweating’ and ‘dry mouth/thirst, mouth com-
plaints’. In the sensitivity analysis, the latter symptom
category was also associated with anticholinergic inhalants,
a drug class used by at least five subjects in our study
population.
4.1 Strengths
Our study had several strengths. First, patients from com-
munity pharmacies all over The Netherlands were inclu-
ded, so the results can be considered to be representative of
the population of community-dwelling patients taking at
least five drugs in long-term use. Second, the detailed
information on actual drug use available at community
pharmacies enabled us to evaluate associations between the
symptoms reported by patients and the ‘very common’ side
effects of their drugs in use. Third, the use of a cut-off point
in the analysis of SPC-related symptoms elucidated the
most likely associations between drugs and symptoms
reported by patients.
4.2 Limitations
Our approach was not without limitations, the first of which
was related to the PROMISE instrument. As PROMISE
only contained 22 predefined symptom categories, other
symptoms, such as sleeplessness or restless legs, may have
been underreported by patients. However, the numbers of
predefined patient-reported symptoms are likely to be
representative due to the structured development of this list
based on the most common side effects of the most fre-
quently used drugs. A second limitation was that the side
effects listed in the SPC had to be translated into the
symptoms used in the PROMISE instrument. To reduce the
risk of interpretation errors, this process was performed
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independently by two researchers. Third, as we mainly
focused on the most common side effects, we may have
missed associations with less common side effects. The
inclusion of less common side effects could have shown
more potentially SPC-associated symptoms but would have
complicated interpretation of our results. Furthermore, as
not all potential side effects are listed in the SPCs, a con-
clusive evaluation would still not be possible. As we
focused on patient-reported symptoms, a fourth limitation
of our study was that the healthcare professionals’ view on
potential drug associations was not included. However, this
is part of the process of a CMR and should be evaluated in
the subsequent trial.
5 Conclusion
Users of at least five drugs in long-term use reported
symptoms and indicated drug associations using the
PROMISE instrument. For a majority of the symptoms
reported, a drug in use with the symptom listed as a ‘very
common’ side effect could be detected in patients’ actual
use. Especially for ‘dry mouth/thirst, mouth complaints’,
‘constipation’, ‘diarrhoea’ and ‘sweating’, additional drugs
with these side effects in use contributed to patients’
symptoms experienced.
Further research is needed to evaluate the use of the
PROMISE instrument to verify and ameliorate potentially
drug-related symptoms as part of the patient interview in
the CMR, and to assess whether this contributes to a
reduction of symptoms experienced by patients as a result
of their drug therapy.
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